Inhibitors of the tyrosine kinase activity of JAK2 have proven efficacious in reducing splenomegaly and improving constitutional symptoms in patients with MPN, particularly MF; however, they do not selectively target the mutated clone and their potential activity is constrained by myelotoxicity, indicating that novel therapeutic strategies should be sought. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.